Abstract
Devising therapies for neurodegenerative diseases remains a major challenge due to the complex etiology, prolonged disease course and the paucity of validated targets. These factors make it difficult to model neurodegenerative diseases in a manner amenable to large-scale screening. However, recent developments in automation, combinatorial chemistry and high-throughput phenotypic assays have presented new opportunities for discovering small molecule therapeutics for neurodegenerative diseases. This review focuses on novel in vitro and phenotypic screens for Huntingtons disease and a few other neurodegenerative diseases. The lessons learned from these screens and the potential of the small molecules identified as therapeutic leads are discussed.
Keywords: Drug discovery, huntington's disease, models, polyglutamine disease, screening, therapy, Amyotrophic Lateral Sclerosis, ALS, SMER's, small molecule enhancers of rapamy, synuclein, FGF-2, CNTF, brain derived growth factor, BDNF, Fluorescence Resonance Energy transfer, FRET, Y-27632, spinocerebellar ataxia-1, SCA-1, su-peroxide dismutase, SOD, caffeic acid phenylethyl ester, CAPE
Current Molecular Pharmacology
Title: Drug Screening for Huntingtons Disease and other Neurodegenerative Disorders
Volume: 3
Author(s): Hemant Varma
Affiliation:
Keywords: Drug discovery, huntington's disease, models, polyglutamine disease, screening, therapy, Amyotrophic Lateral Sclerosis, ALS, SMER's, small molecule enhancers of rapamy, synuclein, FGF-2, CNTF, brain derived growth factor, BDNF, Fluorescence Resonance Energy transfer, FRET, Y-27632, spinocerebellar ataxia-1, SCA-1, su-peroxide dismutase, SOD, caffeic acid phenylethyl ester, CAPE
Abstract: Devising therapies for neurodegenerative diseases remains a major challenge due to the complex etiology, prolonged disease course and the paucity of validated targets. These factors make it difficult to model neurodegenerative diseases in a manner amenable to large-scale screening. However, recent developments in automation, combinatorial chemistry and high-throughput phenotypic assays have presented new opportunities for discovering small molecule therapeutics for neurodegenerative diseases. This review focuses on novel in vitro and phenotypic screens for Huntingtons disease and a few other neurodegenerative diseases. The lessons learned from these screens and the potential of the small molecules identified as therapeutic leads are discussed.
Export Options
About this article
Cite this article as:
Varma Hemant, Drug Screening for Huntingtons Disease and other Neurodegenerative Disorders, Current Molecular Pharmacology 2010; 3 (3) . https://dx.doi.org/10.2174/1874467211003030164
DOI https://dx.doi.org/10.2174/1874467211003030164 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cellular, Molecular and Non-Pharmacological Therapeutic Advances for the Treatment of Parkinson's Disease: Separating Hope from Hype
Current Gene Therapy Longevity Pathways (mTOR, SIRT, Insulin/IGF-1) as Key Modulatory Targets on Aging and Neurodegeneration
Current Topics in Medicinal Chemistry Serum Vitamin E (α-Tocopherol) Estimation: A Potential Biomarker of Antioxidant Status Evaluation on Heavy Metal Toxicities
Recent Patents on Biomarkers Involvement of the Septo-Hippocampal Cholinergic Pathway in Association with Septal Acetylcholinesterase Upregulation in a Mouse Model of Tauopathy
Current Alzheimer Research Chemistry and Biology of Thyrotropin-Releasing Hormone (TRH) and its Analogs
Current Medicinal Chemistry Endoplasmic Reticulum Dysfunction in Brain Pathology: Critical Role of Protein Synthesis
Current Neurovascular Research Patent Selections:
Recent Patents on Regenerative Medicine Current Therapeutic Strategies and Perspectives for Neuroprotection in Parkinson’s Disease
Current Pharmaceutical Design Efficacy of Vitamins B Supplementation on Mild Cognitive Impairment and Alzheimer`s Disease: A Systematic Review and Meta-Analysis
Current Alzheimer Research Autophagy after Subarachnoid Hemorrhage: Can Cell Death be Good?
Current Neuropharmacology Commentary Research Highlights: Untangling Alzheimer Disease Pathology
CNS & Neurological Disorders - Drug Targets Nutraceuticals and their Novel Drug Delivery System: A Boon to Human Health
Current Nutrition & Food Science Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design Wnt1 Inducible Signaling Pathway Protein 1 (WISP1) Targets PRAS40 to Govern β-Amyloid Apoptotic Injury of Microglia
Current Neurovascular Research Meet Our Editorial Board Member
Current Neuropharmacology The Prospect of Stem Cells as Multi-Faceted Purveyors of Immune Modulation, Repair and Regeneration in Multiple Sclerosis
Current Stem Cell Research & Therapy Editorial (Thematic Issue: Molecular and Cellular Engineering Approaches for Neurological Disorders, Diseases, and Injuries Involved the Central and Peripheral Nervous Systems)
CNS & Neurological Disorders - Drug Targets Arachidonic Acid Metabolites in Neurologic Disorders
CNS & Neurological Disorders - Drug Targets Targeting Heme Oxygenase-1 for Neuroprotection and Neuroinflammation in Neurodegenerative Diseases
Current Drug Targets Adult Neural Stem Cells: Response to Stroke Injury and Potential for Therapeutic Applications
Current Stem Cell Research & Therapy